Lates News

Analysts shared data from IQVIA on Friday, showing that within the first four days of the launch of the oral tablet form of the weight loss drug Wegovy by Novo Nordisk in the United States, 3,071 prescriptions were written. Investors are closely watching whether the company can solidify its first-mover advantage over competitors in the competitive weight loss drug market. Barclays analysts pointed out in their report that these data only reflect the prescription volume of oral Wegovy through retail channels and do not include prescriptions distributed through Novo Nordisk's own NovoCare Pharmacy online channel, so the actual number of prescriptions will be higher.